Alpine Immune Sciences (NASDAQ:ALPN) Sets New 1-Year High at $64.72

Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $64.72 and last traded at $64.70, with a volume of 748953 shares traded. The stock had previously closed at $64.64.

Analysts Set New Price Targets

ALPN has been the topic of several research reports. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $65.00 target price (up previously from $41.00) on shares of Alpine Immune Sciences in a research report on Thursday, April 11th. Oppenheimer reissued an “outperform” rating and set a $44.00 target price (up previously from $33.00) on shares of Alpine Immune Sciences in a report on Tuesday, March 19th. Guggenheim assumed coverage on shares of Alpine Immune Sciences in a research report on Tuesday, April 9th. They issued a “buy” rating and a $55.00 target price for the company. Leerink Partnrs lowered shares of Alpine Immune Sciences from an “outperform” rating to a “market perform” rating in a research report on Thursday, April 11th. Finally, TD Cowen reiterated a “hold” rating on shares of Alpine Immune Sciences in a research note on Tuesday, April 16th. Eight investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $50.33.

Alpine Immune Sciences Stock Performance

The firm’s fifty day simple moving average is $48.01 and its 200 day simple moving average is $29.53. The stock has a market capitalization of $4.24 billion, a P/E ratio of -101.09 and a beta of 0.97.

Alpine Immune Sciences (NASDAQ:ALPN) last announced its quarterly earnings data on Monday, March 18th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.47. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. The business had revenue of $30.85 million for the quarter, compared to analysts’ expectations of $6.90 million. Analysts anticipate that Alpine Immune Sciences, Inc. will post -1.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. bought a new position in shares of Alpine Immune Sciences in the first quarter worth about $27,000. Bank of New York Mellon Corp lifted its stake in Alpine Immune Sciences by 1.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 92,723 shares of the biotechnology company’s stock valued at $1,062,000 after purchasing an additional 1,216 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its position in Alpine Immune Sciences by 745.5% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,488 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 1,312 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Alpine Immune Sciences during the first quarter worth $106,000. Finally, Barclays PLC increased its holdings in shares of Alpine Immune Sciences by 44.3% during the third quarter. Barclays PLC now owns 9,126 shares of the biotechnology company’s stock worth $104,000 after buying an additional 2,801 shares in the last quarter. Institutional investors own 75.17% of the company’s stock.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.